Obsessive Compulsive Disorder (OCD). Obsessive-compulsive disorder
Conditions
Interventions
Intervention 1: Intervention group: This group, which includes subjects with a diagnosis of obsessive-compulsive disorder, will receive memantine hydrochloride (C12H21N•HCl) 10 mg twice daily in two 8
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Definitive diagnosis of obsessive-compulsive disorder based on the psychiatrist assessment and its confirmation according to SCID-5 (Structured-Clinical Interview for DSM5) by the clinical psychologist Y-BOCS Score equal or more than 16 for obsessions and compulsions or equal or more than 10 only for obsessions or compulsions. Being in The age range of 18-50 IQ level more than 80 based on Wechsler Adult Intelligence Scale Signing written informed consent
Exclusion criteria
Exclusion criteria: Subjects with major depressive disorder, bipolar disorder, personality disorder, and schizophrenia in a way that questions the diagnose of obsessive-compulsive disorder. Pregnancy, lactation or the imminent possibility of either of these cases or use of birth control methods for female subjects (these items will be assessed by the validated urine tests) Past or current drug/alcohol abuse or dependence (these items will be assessed by the urine toxicology tests) Previous exposure to any kind of psychotropic medication (benzodiazepines, antipsychotics, antidepressants, stimulants, mood stabilizers) Previous exposure to at least 8 sessions of structured psycho-therapeutic courses Past history or current existence of neurological diseases (seizures, epilepsy syndromes, history of trauma, stroke, loss of consciousness) and other severe internal and surgical disorders Presence of any contraindication to MRI scanning, including metal implants or claustrophobia. Metal implants, pacemaker, other metal (e.g. shrapnel or surgical prostheses) or paramagnetic objects contained within the body which may present a risk to the subject or interfere with the MR scan, as determined in consultation with a neuroradiologist and according to the guidelines set forth in the following reference book commonly used by the neuroradiologists:"Guide to MR procedures and metallic objects", F. G. Increase in liver enzymes SGOT and SGPT more than threefold compared with baseline levels.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Symptom (Obsession and Compulsions) Severity Based on Yale Brown Obsessive Compulsive Disorder Scale. Timepoint: Assessment of Severity and pattern of symptoms : at the beginning of study and before the beginning of intervention, 2 weeks after the beginning of intervention, 4 weeks after the beginning of intervention, 6 weeks after the beginning of intervention, 8 weeks after the beginning of intervention,10 weeks after the beginning of intervention, 12 weeks after the beginning of intervention. Method of measurement: Validated Yale Brown Obsessive Compulsive Disorder Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Neuro-Cognitive Functions. Timepoint: At the beginning of the study and then after 6th week and 12th week. Method of measurement: The Cambridge Neuropsychological Test Automated Battery (CANTAB).;Functional organization of Large-Scale Brain Networks. Timepoint: At the Beginning of Study and then after 6th week and 12th week. Method of measurement: Functional Magnetic Resonance Imaging. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMahmoudreza Hadjighassem
Tehran University of Medical Sciences
Outcome results
None listed